Literature DB >> 23927665

Cognitive interviewing in risk minimization survey development: patient and healthcare professional surveys.

Dana B DiBenedetti1, Mark A Price, Elizabeth B Andrews.   

Abstract

Risk minimization programs are often required for selected drugs and other products to ensure that the benefits of these prescription products outweigh their risks. Regulators in the USA and Europe have recently called for more rigorous standards in developing measures for risk minimization program assessment. Cognitive pretesting interviews are a critical step in the development of survey instruments used to evaluate patients' and healthcare professionals' knowledge and behaviors associated with the safe use of products requiring a risk minimization program. This article is intended as a guide for the researcher who is charged with the development of survey instruments used in these programs and focuses on the role of cognitive pretesting interviews in successful survey instrument design, data analysis and interpretation.

Entities:  

Mesh:

Year:  2013        PMID: 23927665     DOI: 10.1586/17512433.2013.811824

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  3 in total

1.  Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis.

Authors:  Aaron Salwan; Nicholas E Hagemeier; Fred Tudiver; KariLynn Dowling-McClay; Kelly N Foster; Jessie Arnold; Arsham Alamian; Robert P Pack
Journal:  J Am Pharm Assoc (2003)       Date:  2020-07-12

2.  The association between insurance type and cost-related delay in care: a survey.

Authors:  Sora Al Rowas; Michael B Rothberg; Benjamin Johnson; Joel Miller; Mohanad AlMahmoud; Jennifer Friderici; Sarah L Goff; Tara Lagu
Journal:  Am J Manag Care       Date:  2017-07       Impact factor: 2.229

3.  Refinement of the symptom screening in pediatrics tool (SSPedi).

Authors:  C O'Sullivan; L L Dupuis; P Gibson; D L Johnston; C Baggott; C Portwine; B Spiegler; S Kuczynski; D Tomlinson; S de Mol Van Otterloo; G A Tomlinson; L Sung
Journal:  Br J Cancer       Date:  2014-08-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.